Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2020-05-29 Declaration of Voting R…
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Number of shares and votes in Oncopeptides
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a press release dated May 29, 2020, announcing a change in the number of shares and votes due to a directed share issue carried out in May 2020. This directly relates to a change in the company's capital structure (increase in outstanding shares and share capital). According to the definitions, 'Capital/Financing Update' (CAP) covers updates on company fundraising, financing activities, or capital structure changes. While 'Share Issue/Capital Change' (SHA) is also relevant, 'CAP' is often used for announcements detailing the immediate impact of financing activities like share issues on the total count, whereas SHA might be reserved for broader structural changes or specific share issuance mechanisms. Given the focus on the resulting share count change from a recent issue, CAP is the most appropriate fit, although SHA is a close secondary possibility. Since the text explicitly details the increase in shares and capital resulting from a financing event, CAP is selected.
2020-05-29 English
Antal aktier och röster i Oncopeptides
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a press release dated May 29, 2020, announcing a change in the total number of outstanding shares and votes following a directed new share issue ('riktad nyemission'). This directly relates to changes in the company's capital structure and share count. This aligns best with the 'Share Issue/Capital Change' definition (Code: SHA). It is not a full financial report (10-K, IR), an earnings release (ER), or a dividend notice (DIV).
2020-05-29 Swedish
Oncopeptides reinitiates patient enrollment to the melflufen clinical program following a temporary pause due to the COVID-19 pandemic
Regulatory Filings Classification · 1% confidence The document is explicitly labeled as a "Press release" dated May 28, 2020, from Oncopeptides AB. It announces a specific operational update: the reinitiation of patient enrollment in their clinical program following a COVID-19 related pause. It discusses clinical studies (HORIZON, ANCHOR, BRIDGE, LIGHTHOUSE), regulatory submissions (FDA), and provides contact information for Investor Relations. This type of announcement, detailing operational progress, clinical trial status, and general company news via a press release format, is typically classified as a general Regulatory Filing or an announcement that doesn't fit the specific financial report categories (like 10-K, ER, or IR). Since it is a formal announcement required for market transparency (as indicated by the EU Market Abuse Regulation mention), and it is not a specific financial report, dividend notice, or management change, the most appropriate general category is Regulatory Filings (RNS). It is too detailed for a simple Report Publication Announcement (RPA) as it contains substantive operational news, not just a notice about another report being available.
2020-05-28 English
Oncopeptides återupptar patientrekryteringen till kliniska utvecklingsprogrammet för melflufen efter att den tillfälligt pausats på grund av COVID-19-pandemin
Regulatory Filings Classification · 1% confidence The document is a press release dated May 28, 2020, issued by Oncopeptides AB. It announces the resumption of patient recruitment for their clinical development program for melflufen following a temporary pause due to COVID-19. It discusses ongoing clinical trials (HORIZON, ANCHOR, BRIDGE, AL Amyloidos, LIGHTHOUSE), regulatory timelines (FDA submission planned for Q2 end), and provides background information on the drug and the company. This type of announcement, detailing operational updates, clinical progress, and regulatory milestones, is characteristic of general corporate communications aimed at investors and the market, but it is not a formal financial report (like 10-K or IR), a specific management discussion (MDA), or a formal earnings release (ER). Since it is a general regulatory announcement concerning business operations and clinical progress, and it doesn't fit neatly into the other specific categories (like DIRS, DIV, CAP, etc.), the most appropriate fallback category is Regulatory Filings (RNS), as it is a 'Pressmeddelande' (Press Release) published under EU market abuse regulation requirements.
2020-05-28 Swedish
Kommuniké från årsstämma i Oncopeptides AB (publ)
AGM Information Classification · 1% confidence The document is titled "Kommuniké från årsstämma i Oncopeptides AB (publ)" which translates to "Communiqué from the Annual General Meeting in Oncopeptides AB (publ)". The text details the key decisions made at the AGM held on May 26, 2020, including the approval of the annual report, election of board members, and decisions regarding remuneration guidelines and incentive programs. This content directly relates to the proceedings and outcomes of an Annual General Meeting. Therefore, the appropriate classification is AGM Information (AGM-R). The document length (4624 chars) is substantial enough to be the primary communication, not just a brief announcement of a report.
2020-05-26 Swedish
Bulletin from the Annual General Meeting in Oncopeptides AB (publ)
AGM Information Classification · 1% confidence The document is explicitly titled "Bulletin from the Annual General Meeting in Oncopeptides AB (publ)" and details the resolutions passed during the meeting, such as the adoption of the annual report, approval of remunerations, re-election of board members, and authorization for future share issuance. These are core activities and outcomes of an Annual General Meeting (AGM). Therefore, the classification should be AGM Information (AGM-R).
2020-05-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.